26.39
전일 마감가:
$26.31
열려 있는:
$26.39
하루 거래량:
3.96M
Relative Volume:
2.56
시가총액:
$2.49B
수익:
$522.75M
순이익/손실:
$-558.99M
주가수익비율:
-4.0788
EPS:
-6.47
순현금흐름:
$-439.53M
1주 성능:
-9.72%
1개월 성능:
-28.94%
6개월 성능:
-36.07%
1년 성능:
-37.98%
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
RARE을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RARE
Ultragenyx Pharmaceutical Inc
|
26.39 | 2.76B | 522.75M | -558.99M | -439.53M | -6.47 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-28 | 개시 | William Blair | Outperform |
2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-06-14 | 재개 | Credit Suisse | Outperform |
2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
2023-01-18 | 재개 | Canaccord Genuity | Buy |
2022-12-30 | 재개 | H.C. Wainwright | Buy |
2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
2021-09-30 | 개시 | H.C. Wainwright | Buy |
2021-08-19 | 개시 | UBS | Sell |
2021-07-15 | 개시 | Guggenheim | Neutral |
2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
2021-06-04 | 재개 | Robert W. Baird | Neutral |
2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
2021-04-26 | 재개 | Credit Suisse | Neutral |
2021-03-02 | 재개 | Stifel | Buy |
2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2020-11-24 | 재개 | Evercore ISI | In-line |
2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
2019-08-02 | 재개 | Wedbush | Outperform |
2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2019-02-22 | 재개 | Raymond James | Outperform |
2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
2018-05-10 | 개시 | Goldman | Neutral |
2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
2018-03-22 | 재개 | Piper Jaffray | Overweight |
2018-02-21 | 재확인 | Stifel | Buy |
2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
2018-01-18 | 개시 | Credit Suisse | Outperform |
2017-12-05 | 재확인 | Barclays | Equal Weight |
2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
What drives Ultragenyx Pharmaceutical Inc. stock priceFree Predictions - jammulinksnews.com
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
What analysts say about Ultragenyx Pharmaceutical Inc. stockExtraordinary market timing - Autocar Professional
11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey
William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN
Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Ultragenyx Pharmaceutical Inc. a good long term investmentTremendous return on equity - Autocar Professional
Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire
Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada
Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsPredictable High Return Trades - Newser
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa
Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com
Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com
Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire
Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN
Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyFree Exclusive Access to Stock Gurus - Newser
Ultragenyx Pharmaceutical Enters Oversold Territory (RARE) - Nasdaq
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA - Yahoo Finance
Ultragenyx Pharmaceutical (RARE): Balancing High-Stakes Catalysts with a Tightening Cash Runway - AInvest
Ultragenyx: The High Stakes Of Binary Events And A Short Cash Runway (RARE) - Seeking Alpha
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $55.00 by Analysts at Morgan Stanley - Defense World
Five things for pharma marketers to know: Tuesday, July 15, 2025 - Medical Marketing and Media
Ultragenyx's Evkeeza Pediatric Approval Positions It as a Rare Disease Leader - AInvest
Ultragenyx’s MPSIIIA Gene Therapy UX111 Met With CRL - CGTLive®
Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data - TipRanks
Ultragenyx Faces Delays After Setrusumab Misses Key Targets - Finimize
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst - Benzinga
FDA rejects Ultragenyx gene therapy over manufacturing concerns - BioPharma Dive
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):